As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focused on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of care. Dementia affects more than 6% of people aged 60+ and has a devastating effect on their independence – to date, there is no proven intervention to help dementia patients live a fulfilling life for longer. In this project we will build on an innovative patient support tool to provide healthcare over a distance specifically targeted to patients with mild dementia that enables the interaction of voice, video, and healthrelated data using ordinary telephone lines connected to internet The aim of this study is to develop and to evaluate the effectiveness of a remote support care system based on transmission of data and video-interactivity between health-professionals, patients and careers to prevent deterioration of health and to improve social connectedness and to improve quality of life of people living at home with dementia. The tool will offers following applications:

i) Interactive video conference system with health professionals
ii) Reminders and alerts to help patients to adhere to their treatment and their medical appointments
iii) Telecare through remote transmission of vital signs data (e.g. blood pressure) and regular monitoring of cognitive functions.
iv) Social Connectedness of patients with their families, to community organizations and to social services.
v) Promotion of Health and healthy style of living of people living with dementia at home through counselling, exercise training by videos and online practices sessions

This will slow the patients’ cognitive and functional decline, avoid carers getting exhausted and reduce costs of emergency care. Our project will comprise two phases: first we promote focus group with doctors, nurses, patients and careers to discuss the content and the materials they consider needed to be included in the interface of support system. Later the device will be tested in the home TV and connected to internet. A demonstration and a training session of device utilization will be made at home with users and careers. We will collect feedback on its adaptation from their users of the application until the design is perfectly adapted to the users’ needs. In the second phase, we will pilot in two different countries the optimized application with a total of 100 users (patients + careers) and 100 controls. This will show the clinical and social benefits for patients and careers, as well as financial benefits for the healthcare system. Successful delivery of the pilot will increase patients’ adherence to treatment (10 %-points), while improving the quality of life of careers and patients and it will save health care providers €1,818 / patient / year in care costs, based in the improvement of treatment adherence.

The Initiative «Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia» that used the results of «TV-AssistDem», is a finalist on «EU Health Award». These awards are annual prices of the European Commission to the best policies of the EU in the field of Health.

Abstrast:

The iniciative seeked to prevent and alleviate mental health related needs and the impact of social isolation as a consequence of the COVID-19 pandemic in community-dwelling older adults with cognitive impairment or dementia by providing television-based and telephone-based health care and social support bridging the gaps which rose from disrupted service provision. Moreover, the effects of a television-based assistive integrated technology TV-ASSISTDEM, for remote support were explored. Findings showed how a presumably vulnerable population presented more resilience to social isolation than expected with overall optimal mental health. However, living alone was reported as a risk factor for negative psychological effects. Health or social services contact during the outbreak was high, and Television sets were the preferred technological devices to access COVID-19 information, watch television as a recreational activity, and perform memory exercises as an intellectual activity.Telehealth support using TV-AssistDem demonstrated potential for cognitive stimulation.

Check the new in our social media

Breaking news

IBIMA has been awarded with a prize of 1.500€ in the EU Health Award on Mental Health in the category NGOs or other not-for-profits organisation.  Congratulations to Dr Fermina Mayoral and his team in this European recognition that rewards the effort of initiatives alleviating the mental health impact of COVID 19.

Initiative title: “Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia”

As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of care. Dementia affects more than 6% of people aged 60+ and has a devastating effect on their independence – to date, there is no proven intervention to help dementia patients live a fulfilling life for longer.

In this project we will build on an innovative patient support tool to develop a mHealth application that is specifically targeted to patients with mild dementia. The tool will help patients to adhere to their treatment and share data with their carers and doctors; carers will use the same application to monitor patients more easily and share their own well-being with doctors. This will slow the patients’ cognitive and functional decline, avoid carers getting exhausted and reduce costs of emergency care.

Our project will comprise two phases: first we will use digital accessibility tools to re-design the existing application for dementia patients. The development will be steered by patients, carers and doctors, through user-centric design: we will collect feedback on each new version of the application until the design is perfectly adapted to the users’ needs. In the second phase we will pilot the optimised application with 1,100 users (patients + carers) and 1,100 controls. This will show the clinical and social benefits for patients and carers, as well as financial benefits for the healthcare system.

Successful delivery of the pilot will increase patients’ adherence to treatment (10 %-points), while improving the quality of life of carers and patients. It will save healthcare providers €1,818 / patient / year in care costs and will generate revenue of over €18 million / year for the consortium (Year 5).

Website of the Project

GAPP Joint Action is aiming at facilitating the development of a common and optimal approach to assess and authorize preparation processes in blood and tissues establishments (BEs and TEs), adapting requirements as prescribed by Article 29 of Directive 2002/98/EC and Article 28 of Directive 2004/23/EC .

Since the directives for these fields were adopted, significant technical developments have taken place and the complexity of preparation processes has greatly increased. Increasing complexity of processing can bring significant quality and functionality improvements for patients, and/or more efficient use of donations, but it can also bring increased risk, particularly as the level of complexity brings the final product towards the borderline with medicinal products.

GAPP will ensure that any possible advantage or outcome is taken into account from two ongoing Public Health Programme projects focused on tissues and cells (EuroGTP and ECCTR) incorporating a need for clinical follow-up data as part of a comprehensive process authorization.GAPP durable output is that a knowledge sharing platform on PPAs will be developed and fed in order to facilitate sharing of information among European Union, Competent Authorities and a number of CA inspectors will be trained specifically to assess and authorize preparation processes of tissues, cells, reproductive cells and blood products.

GAPP objectives are:

1. 1. Increasing consistency and efficacy of competent authority regulatory activities through harmonization of EU-level tools for authorization procedures for preparation processes at blood and tissues establishments
   2. Developing a concept model for a European knowledge-sharing platform that can support CAs in the assessment and evaluation of novel preparation processes of products
   3. Developing an international network of experts that can support CAs in the assessment and evaluation of preparation processes of products, trained by the Joint Action

Website of the Project

Studies suggest that the intestinal microbiome modulates the risk of several chronic diseases, including type 2 diabetes, allergy, cardiovascular disease, and colorectal cancer (CRC). Dietary factors are related to chronic disease risk, and they have been suggested to modulate the composition and function of the gut microbiome.

However, detailed knowledge on the relationship of diet, the microbiome, and chronic disease risk is still limited.

The overarching aim of the knowledge platform is to foster studies on the microbiome, nutrition and health by assembling available information in the field of microbiome research in food, nutrition and health in a comprehensive way, which also includes other disciplines (e.g. food science, metabolomics) that are relevant in the context of microbiome research. The goal is to make this information findable, accessible, interoperable and reusable (FAIR) to the scientific community and to link and provide in-depth information to various stakeholders.

Through these efforts a network of transnational and multidisciplinary collaboration will emerge, that will further develop and increase the impact of microbiome research in human health. Urgent areas of research in this KP were identified to be the roles of microbiome in early infancy, during ageing and in subclinical and clinically manifest disease.

Website of the Project

Food allergy is an immune-based disease that has become an important public health problem that affects children and adults and may be increasing in prevalence.In the US, food allergy affects 5% of children under the age of 5 years and 4% of teens and adults, and its prevalence appears to be on the increase. Globally, it is estimated that over 6% of the population, around 200 to 250 million people, suffer from some food allergies, affecting more than 17 million people only in Europe.

The main objective of this proposal is translating an optical diagnostic technology already proven in which the novel AllerScreening platform is based on, to the clinical routine, addressing a priority healthcare unmet need from the laboratory to the clinic. The unique features of AllerScreening will allow clinicians to early detect main food allergies (at least the 90% of European food allergies) through a simple test using a drop of sera, reducing the cost and technical requirements of the current clinical practice. This new and innovative cost-effective sensing system for the in vitro component diagnosis of food allergies will be feasible thanks to the multiplexed disposable BioKits and the optical Pont-of-Care (PoC) reader in which the novel AllerScreening platform is based on, allowing the adoption of a novel PoC diagnostic device specific for food allergies.

Website of the Project

In the last few years, many examples of blood and medicine delivery drones have been

demonstrated worldwide, which mainly rely on aeronautical experience that is not common in the medical world. Speaking about drone delivery, attention should focus on the most important thing: the transported lifesaving good. Traditional boxes that monitor temperature are not usually in real time, and are not suitable for drone transportation because they are heavy and bulky.

This means that the biomedical characteristics of delivery are of primary importance. A Smart Capsule, equipped with artificial intelligence (AI), is the first system ever proposed to provide a fully autonomous drone delivery service for perishable and high-value medical products, integrating real-time quality monitoring and control. It consists in a smart casing that is able to guide any autonomous aerial vehicle attached to it, specifically designed for transporting blood, organs, tissues, test samples and drugs, among others. The system monitors the conditions of the product (e.g., temperature, agitation and humidity) and adjusts them when needed by exploiting, for instance, vibrations to maintain the required agitation, ensuring that goods are ready to be used as soon as they are delivered.

The Smart Capsule also leverages external temperature to reduce energy uptake from the drone, thus improving the drone’s battery life and flight range. The system replaces the need for specialized drivers and traditional road-bound transportation means, while guaranteeing compliance with all applicable safety regulations. A series of 16 experimental tests was performed to demonstrate the possibility of using the smart capsule to manage the flight and internal good delivery. Eighty-one missions were carried out for a total of 364 min of flight.

The Smart Capsule greatly improves emergency response and efficiency of healthcare systems by reducing delivery times by up to 80% and costs by at least 28%. The Smart Capsule and its enabling technology based on AI for drone deliveries are discussed in this paper. The aim of this work is to show the possibility of managing drone delivery with an AI-based device.

The video, recorded in Malaga, shows how The Smart Capsule is able to transport blood precisely thanks to AI technology.  

Website of the Project

Website of the Project

This project investigates evidence based gamification techniques for eHealth and mHealth and develops a multi-dimensional intervention support architecture/platform in order to improve the efficacy of gamified eHealth products (web-based health tools and health apps). The project will develop advanced game production techniques with ready-to-use toolkits to accelerate the innovation process for eHealth and mHealth products. This will help digital industry (games, IoT and ICT) to innovate new products and services with science and technology underpinnings.

It addresses fundamental issues of gamification for eHealth interventions including its development process and evaluation methods for measuring its efficacy. The outcomes of the project, manifested as gamification Toolkits, an integrated ICT Platform, and clinical assessment Methodologies as whole as a framework, will greatly accelerate the pace and scale of eHealth innovation by transforming and increasing its quality and efficiency through advanced technology tools, frameworks and methodologies. By using gamified physical activity engagement as a clinical intervention case study, the proposed framework will be evaluated and tested within patients in primary care settings, who are identified as physical inactive and at risk for their conditions due to sedentary behaviours. However, the gamification framework remains flexible and portable to other contexts of digital health interventions.

• • The project presents two key innovation components:
    An innovative collaborative R&D programme in collaboration with industry, focus on delivering solutions to address challenges in the development process of gamified eHealth products i.e. productivity and efficacy.
  • A strong and sustainable model of collaboration with digital industry and other relevant stakeholders fully integrated to develop the innovation capacity in SMEs in eHealth products, specifically gamified eHealth products and services

Website of the Project

“Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currently the potential of this effort is not realised.

The conect4children (c4c) project will address the critical problems with the design, implementation and operational conduct of paediatric clinical trials, for example the fragmented and redundant efforts between sponsors, sites and countries.
This project will generate a sustainable infrastructure that optimises the delivery of clinical trials in children through: a) a single point of contact for all sponsors, sites and investigators; b) efficient implementation of trials adopting consistent approaches, aligned quality standards and coordination of sites at national and international level; c) collaboration with specialist networks; d) high quality input to study design and preparation through rigorous strategic and operational feasibility assessment and e) the promotion of innovative methodologies.

The project will be managed according to IMI2 best practice with a dedicated communications effort. The clinical trials infrastructure will be setup, implemented and tested by implementing 3-4 industry and at least 1 non-industry proof-of-viability studies. Expert advice groups will promote innovative methodologies and engagement with regulators. The business model for a sustainable infrastructure will be based on the European landscape of paediatric networks and available trial sites, the evaluation of services needs of sponsors of all kinds, and will be informed by the proof-of-viability studies. Supporting activities will include: data management (data about the trials and the network, including performance metrics for network management and promotion; handling trial data for non-industry sponsors; support for common data dictionaries); education and training.
The voices of children, young people and their families will be central to the network.”

Website of the Project